review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | C Nelson Hayes | Q87781870 |
Kazuaki Chayama | Q87781872 | ||
Yoshiiku Kawakami | Q114882129 | ||
P2093 | author name string | Waka Ohishi | |
P2860 | cites work | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 |
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease | Q27473126 | ||
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region | Q27478292 | ||
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients | Q27487949 | ||
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. | Q27690869 | ||
Global epidemiology of hepatitis C virus infection | Q27860799 | ||
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease | Q29614208 | ||
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
Telaprevir for retreatment of HCV infection | Q29619799 | ||
Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
Course and outcome of hepatitis C | Q29620057 | ||
The global burden of hepatitis C | Q29620138 | ||
Natural history of chronic hepatitis C | Q29620673 | ||
Preliminary study of two antiviral agents for hepatitis C genotype 1. | Q34030288 | ||
Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects | Q34226129 | ||
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 | ||
Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C | Q35838595 | ||
American Gastroenterological Association technical review on the management of hepatitis C. | Q36364156 | ||
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C | Q36371508 | ||
Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection | Q36645372 | ||
Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. | Q36670297 | ||
Hepatitis C virus: How genetic variability affects pathobiology of disease | Q37825652 | ||
Hepatitis C virus resistance to protease inhibitors | Q37834102 | ||
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin | Q37972759 | ||
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients | Q37980539 | ||
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice | Q39807236 | ||
National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population | Q40388576 | ||
Epidemiology of Hepatitis C in the West | Q40435898 | ||
Genetic heterogeneity of hepatitis C virus. | Q40564932 | ||
Projecting future complications of chronic hepatitis C in the United States | Q40594872 | ||
Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology | Q42979944 | ||
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. | Q42980375 | ||
Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads | Q42982601 | ||
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. | Q42993815 | ||
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | Q43032179 | ||
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest | Q43033968 | ||
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients | Q43036643 | ||
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo | Q43037298 | ||
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir | Q43037585 | ||
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 | ||
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients | Q43039768 | ||
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders | Q43041150 | ||
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. | Q43041414 | ||
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus | Q43042207 | ||
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan | Q43161784 | ||
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. | Q44643929 | ||
Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. | Q50558312 | ||
P433 | issue | 1 | |
P921 | main subject | Japan | Q17 |
peptide | Q172847 | ||
mechanism of action | Q3271540 | ||
Hepatitis C virus | Q708693 | ||
RNA virus infectious disease | Q18967413 | ||
antiviral agent | Q40207875 | ||
chronic hepatitis C | Q55779873 | ||
chronic hepatitis | Q62019625 | ||
P304 | page(s) | 1-12 | |
P577 | publication date | 2012-11-28 | |
2013-01-01 | |||
P1433 | published in | Journal of Gastroenterology | Q15764399 |
P1476 | title | Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines | |
P478 | volume | 48 |
Q43527241 | A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study |
Q34513827 | A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors |
Q42252352 | Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study |
Q36689877 | Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study |
Q50272981 | Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. |
Q40060636 | Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection. |
Q41930211 | Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. |
Q40964348 | Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. |
Q37093573 | Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. |
Q35078358 | HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study |
Q37615658 | Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials |
Q40460374 | ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. |
Q40279001 | Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C. |
Q42201546 | Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan |
Q41161023 | MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection |
Q40375437 | New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. |
Q45846064 | Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. |
Q42231673 | Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies |
Q38249065 | Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection |
Q39675766 | Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. |
Q35754227 | Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin |
Q42247557 | Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. |
Q37726632 | Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir |
Q38376454 | Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients |
Q86103385 | Response to "treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'?" |
Q42212457 | Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism. |
Q41070380 | Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing |
Q46085179 | Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. |
Q88495710 | The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan |
Q43435689 | Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'? |